Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Clozapine
|
| gptkbp:approves |
gptkb:1990
gptkb:FDA |
| gptkbp:associated_with |
improvement in negative symptoms of schizophrenia
lower risk of tardive dyskinesia |
| gptkbp:brand |
gptkb:Clozapine
|
| gptkbp:class |
atypical antipsychotics
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe renal impairment
bone marrow suppression severe hepatic impairment |
| gptkbp:developed_by |
gptkb:Sandoz
|
| gptkbp:discontinued |
in patients with history of agranulocytosis
|
| gptkbp:dosage_form |
300-900 mg/day
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
orally disintegrating tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Clozaril
|
| gptkbp:ingredients |
gptkb:clozapine
C18 H19 Cl N4 |
| gptkbp:interacts_with |
other antipsychotics
CY P3 A4 inducers CY P1 A2 inhibitors |
| gptkbp:introduced |
1990s
|
| gptkbp:invention |
gptkb:2006
|
| gptkbp:is_atype_of |
N05 A H02
|
| gptkbp:is_available_in |
liquid form
tablet form |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_monitored_by |
white blood cell count
ANC levels |
| gptkbp:is_used_for |
treatment of schizophrenia
|
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
dizziness
fatigue nausea fever sore throat vomiting seizures drowsiness constipation dry mouth weight gain skin rash tachycardia agranulocytosis hypersalivation |
| gptkbp:suitable_for |
elderly patients with dementia-related psychosis
|